Pulmonx Corp. (LUNG): Price and Financial Metrics
GET POWR RATINGS... FREE!
LUNG Stock Price Chart Interactive Chart >
LUNG Price/Volume Stats
| Current price | $44.36 | 52-week high | $69.48 |
| Prev. close | $44.63 | 52-week low | $35.81 |
| Day low | $43.86 | Volume | 274,600 |
| Day high | $44.91 | Avg. volume | 333,605 |
| 50-day MA | $43.48 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 1.61B |
Pulmonx Corp. (LUNG) Company Bio
Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.
Latest LUNG News From Around the Web
Below are the latest news stories about Pulmonx Corp that investors may wish to consider to help them evaluate LUNG as an investment opportunity.
Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/EmphysemaNew Data Presented at ATS 2021 International Conference Shows Positive, Sustained Benefits to Patients Treated with this First Minimally Invasive, Non-drug Treatment OptionREDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that key long-term follow-up data from the TRANSFORM® study was presented at the American Thoracic Society (ATS) virtual 2021 International Conference. The new data confirm the long-term benefits of the Zephyr® Endobronchial Valve (Zephyr Valve), the first minimally invasive procedure to treat patients with severe COPD/emphysema. The study shows that the Zephyr Valves provide significant benefits to patients including improvements ove... |
Pulmonx Corporation 2021 Q1 - Results - Earnings Call PresentationThe following slide deck was published by Pulmonx Corporation in conjunction with their 2021 Q1 earnings call.... |
Pulmonx Corporation (NASDAQ:LUNG) Released Earnings Last Week And Analysts Lifted Their Price Target To US$60.14Pulmonx Corporation ( NASDAQ:LUNG ) defied analyst predictions to release its first-quarter results, which were ahead... |
Pulmonx Reports First Quarter 2021 Financial ResultsREDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021. Recent Highlights Reported worldwide revenue of $9.2 million in the first quarter of 2021, a 7% increase over the same period last yearAchieved gross margin of 71.5% in the first quarter of 2021 as compared to 65.6% in the same period last yearIncreased number of U.S. Zephyr Valve treating centers from 148 to 160Expanded U.S. sales management team from 6 to 9 regional directors while increasing total number of U.S. sales territory managers from 45 to 51Experienced a recovery in U.S. procedures in March as hospital constr... |
Pulmonx Corporation Expands Leadership TeamREDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the appointment of Michael Ryan as Vice President, Corporate Strategy and Business Development, and the earlier appointments of David Lehman as General Counsel, and Mahtab Fatemi as Vice President, Regulatory Affairs and Quality Assurance. “We could not be more excited to have these three deeply experienced professionals on the Pulmonx team. Each of these individuals is uniquely qualified and brings a wealth of insight and knowledge about the medical device business to their respective areas of responsibility,” said Glen French, President and CEO of Pulmonx. Mr. Ryan, who will lead all corporate st... |
LUNG Price Returns
| 1-mo | 16.68% |
| 3-mo | -26.60% |
| 6-mo | -4.75% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -35.73% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...